arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo


           
|
              http://www.jhasim1.com/index.aspx?case_id=31
 
OVERVIEW
In the United States, lung cancer remains the leading cause of cancer mortality in both men and women, with more than 50% of patients presenting with locally advanced, inoperable, or metastatic disease. Approximately 33% of patients with non–small-cell lung cancer (NSCLC) present with advanced-stage disease while most patients with early stage NSCLC will eventually develop metastatic lung cancer. Despite the numerous therapeutic options available, only 15% of patients with lung cancer survive beyond 5 years from diagnosis. Recent advances in genetic and histological markers, coupled with emerging targeted agents for NSCLC, have the potential to improve patient outcomes. There also has been much progress in the treatment of advanced NSCLC in the last several years as clinical trials have demonstrated improved outcomes with novel therapeutic agents directed against a wide array of molecular targets. Pathologists function in several broad areas, including as diagnosticians and investigators, and are uniquely positioned to assist oncologists with the development of a comprehensive treatment plan. The following educational activity consists of 4 interactive modules. Each activity will present different case scenarios, using the latest treatment options and diagnostic markers to help pathologists improve patient outcomes.

GOAL
To provide pathologists with up-to-date information on the diagnosis and management of patients with NSCLC.

TARGET AUDIENCE
This activity is designed for pathologists. No prerequisites required.

LEARNING OBJECTIVES
After completing this activity, the participant will demonstrate the ablity to:

  • Describe the prognostic and predictive role of histologic and immunohistochemical markers in NSCLC therapy.
  • Based on tumor biology, evaluate current and emerging therapeutic strategies that incorporate targeted agents with chemotherapy for patients with advanced NSCLC.
  • Recognize how gene expression profiling and mutation analysis may help to customize therapy for patients with NSCLC.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.



Johns Hopkins Advanced Studies in Medicine (ISSN-1558-0334), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2012 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.